Report cover image

Global Peptide CDMO Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 111 Pages
SKU # APRC20353704

Description

Summary

According to APO Research, The global Peptide CDMO market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global companies of Peptide CDMO include Xinbang Pharma, ScinoPharm, SN Biopharm, Genscript, AmbioPharm, USV Peptides, Thermofischer, PolyPeptide and Piramal Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Peptide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide CDMO.

The Peptide CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Peptide CDMO Segment by Company

Xinbang Pharma
ScinoPharm
SN Biopharm
Genscript
AmbioPharm
USV Peptides
Thermofischer
PolyPeptide
Piramal Pharma
JPT
CPC Scientific
CordenPharma
CBL
Bio Basic
Bachem

Peptide CDMO Segment by Type

APIs and Intermediates
FDF

Peptide CDMO Segment by Application

Commercial
Academic Research
Other

Peptide CDMO Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Peptide CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report

Table of Contents

111 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Peptide CDMO Market Size Overview by Region 2020 VS 2024 VS 2031
1.4 Global Peptide CDMO Market Size by Region (2020-2031)
1.4.1 Global Peptide CDMO Market Size by Region (2020-2025)
1.4.2 Global Peptide CDMO Market Size by Region (2026-2031)
1.5 Key Regions Peptide CDMO Market Size (2020-2031)
1.5.1 North America Peptide CDMO Market Size Growth Rate (2020-2031)
1.5.2 Europe Peptide CDMO Market Size Growth Rate (2020-2031)
1.5.3 Asia-Pacific Peptide CDMO Market Size Growth Rate (2020-2031)
1.5.4 South America Peptide CDMO Market Size Growth Rate (2020-2031)
1.5.5 Middle East & Africa Peptide CDMO Market Size Growth Rate (2020-2031)
2 Peptide CDMO Market by Type
2.1 Type Introduction
2.1.1 APIs and Intermediates
2.1.2 FDF
2.2 Global Peptide CDMO Market Size by Type
2.2.1 Global Peptide CDMO Market Size Overview by Type (2020-2031)
2.2.2 Global Peptide CDMO Historic Market Size Review by Type (2020-2025)
2.2.3 Global Peptide CDMO Market Size Forecasted by Type (2026-2031)
2.3 Global Peptide CDMO Market Size by Regions
2.3.1 North America Peptide CDMO Market Size Breakdown by Type (2020-2025)
2.3.2 Europe Peptide CDMO Market Size Breakdown by Type (2020-2025)
2.3.3 Asia-Pacific Peptide CDMO Market Size Breakdown by Type (2020-2025)
2.3.4 South America Peptide CDMO Market Size Breakdown by Type (2020-2025)
2.3.5 Middle East and Africa Peptide CDMO Market Size Breakdown by Type (2020-2025)
3 Peptide CDMO Market by Application
3.1 Type Introduction
3.1.1 Commercial
3.1.2 Academic Research
3.1.3 Other
3.2 Global Peptide CDMO Market Size by Application
3.2.1 Global Peptide CDMO Market Size Overview by Application (2020-2031)
3.2.2 Global Peptide CDMO Historic Market Size Review by Application (2020-2025)
3.2.3 Global Peptide CDMO Market Size Forecasted by Application (2026-2031)
3.3 Global Peptide CDMO Market Size by Regions
3.3.1 North America Peptide CDMO Market Size Breakdown by Application (2020-2025)
3.3.2 Europe Peptide CDMO Market Size Breakdown by Application (2020-2025)
3.3.3 Asia-Pacific Peptide CDMO Market Size Breakdown by Application (2020-2025)
3.3.4 South America Peptide CDMO Market Size Breakdown by Application (2020-2025)
3.3.5 Middle East and Africa Peptide CDMO Market Size Breakdown by Application (2020-2025)
4 Global Market Dynamics
4.1 Peptide CDMO Industry Trends
4.2 Peptide CDMO Industry Drivers
4.3 Peptide CDMO Industry Opportunities and Challenges
4.4 Peptide CDMO Industry Restraints
5 Competitive Insights by Company
5.1 Global Top Players by Peptide CDMO Revenue (2020-2025)
5.2 Global Peptide CDMO Industry Company Ranking, 2023 VS 2024 VS 2025
5.3 Global Peptide CDMO Key Company Headquarters & Area Served
5.4 Global Peptide CDMO Company, Product Type & Application
5.5 Global Peptide CDMO Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Peptide CDMO Market CR5 and HHI
5.6.2 Global Top 5 and 10 Peptide CDMO Players Market Share by Revenue in 2024
5.6.3 2024 Peptide CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
6.1 Xinbang Pharma
6.1.1 Xinbang Pharma Comapny Information
6.1.2 Xinbang Pharma Business Overview
6.1.3 Xinbang Pharma Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.1.4 Xinbang Pharma Peptide CDMO Product Portfolio
6.1.5 Xinbang Pharma Recent Developments
6.2 ScinoPharm
6.2.1 ScinoPharm Comapny Information
6.2.2 ScinoPharm Business Overview
6.2.3 ScinoPharm Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.2.4 ScinoPharm Peptide CDMO Product Portfolio
6.2.5 ScinoPharm Recent Developments
6.3 SN Biopharm
6.3.1 SN Biopharm Comapny Information
6.3.2 SN Biopharm Business Overview
6.3.3 SN Biopharm Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.3.4 SN Biopharm Peptide CDMO Product Portfolio
6.3.5 SN Biopharm Recent Developments
6.4 Genscript
6.4.1 Genscript Comapny Information
6.4.2 Genscript Business Overview
6.4.3 Genscript Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.4.4 Genscript Peptide CDMO Product Portfolio
6.4.5 Genscript Recent Developments
6.5 AmbioPharm
6.5.1 AmbioPharm Comapny Information
6.5.2 AmbioPharm Business Overview
6.5.3 AmbioPharm Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.5.4 AmbioPharm Peptide CDMO Product Portfolio
6.5.5 AmbioPharm Recent Developments
6.6 USV Peptides
6.6.1 USV Peptides Comapny Information
6.6.2 USV Peptides Business Overview
6.6.3 USV Peptides Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.6.4 USV Peptides Peptide CDMO Product Portfolio
6.6.5 USV Peptides Recent Developments
6.7 Thermofischer
6.7.1 Thermofischer Comapny Information
6.7.2 Thermofischer Business Overview
6.7.3 Thermofischer Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.7.4 Thermofischer Peptide CDMO Product Portfolio
6.7.5 Thermofischer Recent Developments
6.8 PolyPeptide
6.8.1 PolyPeptide Comapny Information
6.8.2 PolyPeptide Business Overview
6.8.3 PolyPeptide Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.8.4 PolyPeptide Peptide CDMO Product Portfolio
6.8.5 PolyPeptide Recent Developments
6.9 Piramal Pharma
6.9.1 Piramal Pharma Comapny Information
6.9.2 Piramal Pharma Business Overview
6.9.3 Piramal Pharma Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.9.4 Piramal Pharma Peptide CDMO Product Portfolio
6.9.5 Piramal Pharma Recent Developments
6.10 JPT
6.10.1 JPT Comapny Information
6.10.2 JPT Business Overview
6.10.3 JPT Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.10.4 JPT Peptide CDMO Product Portfolio
6.10.5 JPT Recent Developments
6.11 CPC Scientific
6.11.1 CPC Scientific Comapny Information
6.11.2 CPC Scientific Business Overview
6.11.3 CPC Scientific Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.11.4 CPC Scientific Peptide CDMO Product Portfolio
6.11.5 CPC Scientific Recent Developments
6.12 CordenPharma
6.12.1 CordenPharma Comapny Information
6.12.2 CordenPharma Business Overview
6.12.3 CordenPharma Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.12.4 CordenPharma Peptide CDMO Product Portfolio
6.12.5 CordenPharma Recent Developments
6.13 CBL
6.13.1 CBL Comapny Information
6.13.2 CBL Business Overview
6.13.3 CBL Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.13.4 CBL Peptide CDMO Product Portfolio
6.13.5 CBL Recent Developments
6.14 Bio Basic
6.14.1 Bio Basic Comapny Information
6.14.2 Bio Basic Business Overview
6.14.3 Bio Basic Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.14.4 Bio Basic Peptide CDMO Product Portfolio
6.14.5 Bio Basic Recent Developments
6.15 Bachem
6.15.1 Bachem Comapny Information
6.15.2 Bachem Business Overview
6.15.3 Bachem Peptide CDMO Revenue, Global Share and Gross Margin (2020-2025)
6.15.4 Bachem Peptide CDMO Product Portfolio
6.15.5 Bachem Recent Developments
7 North America
7.1 North America Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2 North America Peptide CDMO Market Size by Country (2020-2025)
7.3 North America Peptide CDMO Market Size Forecast by Country (2026-2031)
8 Europe
8.1 Europe Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2 Europe Peptide CDMO Market Size by Country (2020-2025)
8.3 Europe Peptide CDMO Market Size Forecast by Country (2026-2031)
9 Asia-Pacific
9.1 Asia-Pacific Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2 Asia-Pacific Peptide CDMO Market Size by Country (2020-2025)
9.3 Asia-Pacific Peptide CDMO Market Size Forecast by Country (2026-2031)
10 South America
10.1 South America Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2 South America Peptide CDMO Market Size by Country (2020-2025)
10.3 South America Peptide CDMO Market Size Forecast by Country (2026-2031)
11 Middle East & Africa
11.1 Middle East & Africa Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2 Middle East & Africa Peptide CDMO Market Size by Country (2020-2025)
11.3 Middle East & Africa Peptide CDMO Market Size Forecast by Country (2026-2031)
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.